Alzheimer's Drug Approved by Health Canada
Lecanemab, a lab-made antibody, aims to slow early stages of Alzheimer's disease by targeting plaques in the brain.
According to the Alzheimer Society of Canada, it is the first disease-modifying Alzheimer's treatment approved for use in the country.
Lecanemab is not a cure and cannot reverse the disease or restore lost memories.
The conditional approval of lecanemab is being called a positive development, raising questions about its effectiveness and availability in Canada.
Lecanemab is given by intravenous infusion and targets the buildup of amyloid plaque in the brain, a hallmark of Alzheimer's disease.
Author's summary: Lecanemab approved to slow early Alzheimer's.
More News
- Palghar Crime News: Armed Robbers Open Fire At Jewellery Shop In Boisar, Flee Leaving Revolver Behind
- Patriots' Rhamondre Stevenson is out for Sunday's game vs Falcons
- 'Love Island's' Huda Mustafa Apologizes After Laughing At Racist Slur Hurled Towards Olandria Carthen
- Madden 26 Player Ratings For Week 9 - Biggest Winners & Losers
- Stephen A. Smith Questions Why Chris Grier Got Fired Before Mike McDaniel After Dolphins' Embarrassing Loss
- Wemby’s Evolution Is Scary: Spurs Phenom Dominates Again, Leaves Heat Defenders Helpless
- Loss to Bucks stunk, but Warriors' Jimmy Butler knows key to returning to 'flowers and daisies'
- Philadelphia Eagles QB Jalen Hurts Dressed As God For Halloween
- Bam Adebayo's evolution into 'three-level scorer' starts with Heat's new offense
- HSE Nursing Service unavailable on Tory Island this weekend - Donegal News